An aromatase inhibitor in combination with Zinc(II) phthalocyanine for targeted therapy of post-menopausal breast cancer
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Porphyrin and Phthalocyanine Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Estrogen receptor-positive (ER+) breast cancer treatment: are multi-target compounds the next promising approach10.1016/j.bcp.2020.113989 ↗
2. Understanding breast cancer-The long and winding road10.1016/j.bbacli.2017.01.001 ↗
3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4. An “Omics” approach to determine the mechanisms of acquired aromatase inhibitor resistance10.1089/omi.2010.0097 ↗
5. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development10.1542/peds.2007-2081 ↗
6. Aromatase inhibitors: role in postmenopausal breast cancer10.1002/ardp.202000081 ↗
7. Harnessing a different dependency: how to identify and target androgen receptor-positive versus quadruple-negative breast cancer10.1007/s12672-017-0314-5 ↗
8. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant10.1136/esmoopen-2016-000062 ↗
9. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer10.1016/S0093-7754(03)00302-6 ↗
10. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and –resistant breast cancer cells10.1016/j.jsbmb.2015.07.018 ↗
11. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy10.2217/nnm-2017-0247 ↗
12. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study
13. Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization, in vitro characterization and cell culture studies10.1088/1361-6528/ac1098 ↗
14. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies10.1016/j.xphs.2019.06.003 ↗
15. Scott · Exemestane. Drugs · 1999 · 58 · 67510.2165/00003495-199958040-00007 ↗
16. Exemestane loaded alginate nanoparticles for cancer treatment: formulation and in vitro evaluation10.1016/j.ijbiomac.2017.07.064 ↗
17. Twelve-month estrogen levels in premenopausal women with hormone receptor–positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy10.1200/JCO.2015.61.2259 ↗
18. A new genetic risk score to predict the outcome of locally advanced or metastatic breast cancer patients treated with first-line exemestane: results from a prospective study10.1016/j.clbc.2018.11.009 ↗
19. Insights on the interaction mechanism of exemestane to three digestive enzymes by multi-spectroscopy and molecular docking10.1016/j.ijbiomac.2021.07.079 ↗
20. Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity
21. Clinical utility of exemestane in the treatment of breast cancer10.2147/IJWH.S69475 ↗
22. Aromatase inhibitors in the breast cancer clinic: focus on exemestane10.1530/ERC-13-0269 ↗
23. Molecular targeted study in tumors: from western medicine to active ingredients of traditional Chinese medicine10.1016/j.biopha.2019.109624 ↗
24. Targeting tumour-supportive cellular machineries in anticancer drug development10.1038/nrd4201 ↗
25. Molecular targeted therapy of cancer: the progress and future prospect10.1016/j.flm.2017.06.001 ↗
26. Molecular targeted therapy: treating cancer with specificity10.1016/j.ejphar.2018.07.034 ↗
27. Photodynamic therapy for cancer10.1038/nrc1071 ↗
28. The present and future role of photodynamic therapy in cancer treatment10.1016/S1470-2045(04)01529-3 ↗
29. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
30. A dual-targeted organic photothermal agent for enhanced photothermal therapy10.1002/anie.201811273 ↗
31. Targeted delivery of chlorin e6 via redox sensitive diselenide-containing micelles for improved photodynamic therapy in cluster of differentiation 44-overexpressing breast cancer10.3389/fphar.2019.00369 ↗
32. Tumor-targeting photodynamic therapy based on folate-modified polydopamine nanoparticles10.2147/IJN.S216194 ↗
33. Photodynamic therapy for treatment of solid tumors-potential and technical challenges10.1177/153303460800700405 ↗
34. Photodynamic therapeutics: basic principles and clinical applications10.1016/S1359-6446(99)01412-9 ↗
35. A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib10.1039/c3cc45487h ↗
36. Silicon phthalocyanines axially disubstituted with erlotinib toward small-molecular-target-based photodynamic therapy10.1002/cmdc.201700384 ↗
37. Dennis. A multifunctional molecular therapeutic agent for targeted and controlled dual chemo- and photodynamic therapy10.1021/acs.jmedchem.0c00893 ↗
38. Photodynamic oncotherapy mediated by gonadotropin-releasing hormone receptors10.1021/acs.jmedchem.7b01216 ↗
39. Water-soluble chlorin/arylaminoquinazoline conjugate for photodynamic and targeted therapy10.1021/acs.jmedchem.9b01294 ↗
40. Hepatocyte-targeting single galactose-appended naphthalimide: a tool for intracellular thiol imaging in vivo10.1021/ja210065g ↗
41. Phthalocyanine–peptide conjugates: receptor-targeting bifunctional agents for imaging and photodynamic therapy10.1021/jm301311c ↗
42. A novel zinc phthalocyanine-indometacin photosensitizer with “Three-in-one” cyclooxygenase-2-driven dual targeting and aggregation inhibition for high-efficient anticancer therapy10.1016/j.dyepig.2021.109997 ↗
43. In vivo covalent cross-linking of photon-converted rare-earth nanostructures for tumour localization and theranostics10.1038/ncomms10432 ↗
44. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy10.7150/thno.3463 ↗
45. A novel tumor and mitochondria dual-targeted photosensitizer showing ultra-efficient photodynamic anticancer activities10.1039/C8CC09456J ↗
46. An epidermal growth factor receptor-targeted and endoplasmic reticulum-localized organic photosensitizer toward photodynamic anticancer therapy10.1016/j.ejmech.2019.111625 ↗
47. Recent advances in supramolecular activatable phthalocyanine-based photosensitizers for anti-cancer therapy10.1016/j.ccr.2021.214155 ↗
48. Stimuli responsive phthalocyanine-based fluorescent probes and photosensitizers10.1016/j.ccr.2017.10.006 ↗
49. Nanostructured phthalocyanine assemblies with protein-driven switchable photoactivities for biophotonic imaging and therapy10.1021/jacs.7b05916 ↗
50. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate10.1002/jcb.20932 ↗
51. A molecular combo of zinc(II) phthalocyanine and tamoxifen derivative for dual targeting photodynamic therapy and hormone therapy10.1021/acs.jmedchem.7b00682 ↗
52. Novel targeted photosensitizer as an immunomodulator for highly efficient therapy of T-Cell acute lymphoblastic leukemia10.1021/acs.jmedchem.0c01072 ↗
53. J-aggregates: from serendipitous discovery to supramolecular engineering of functional dye materials10.1002/anie.201002307 ↗
54. Exchange narrowing of the J band of molecular dye aggregates10.1063/1.2823730 ↗
55. Theory of the J-band: fom the frenkel exciton to charge transfer10.1016/j.phpro.2009.07.014 ↗
56. Synthesis, properties, and photodynamic inactivation of Escherichia coli using a cationic and a noncharged Zn(II) pyridyloxyphthalocyanine derivatives10.1016/j.bmc.2005.01.063 ↗
57. Photosensitizer delivery and photosensitization for enhanced photodynamic therapy with ultralow irradiance10.1002/adfm.201402255 ↗
58. Synthesis and in vitro biological evaluation of lipophilic cation conjugated photosensitizers for targeting mitochondria10.1016/j.bmc.2012.11.032 ↗
59. A near-infrared triggered nanophotosensitizer inducing domino effect on mitochondrial reactive oxygen species burst for cancer therapy10.1021/acsnano.5b04501 ↗
60. Acidity-triggered tumor-targeted chimeric peptide for enhanced intra-nuclear photodynamic therapy10.1002/adfm.201600170 ↗